Hikma Pharmaceuticals (LON:HIK) had its target price raised by JPMorgan Chase & Co. from GBX 1,700 ($22.21) to GBX 1,800 ($23.52) in a research report released on Tuesday, Stock Target Advisor reports. They currently have a neutral rating on the stock.
Other research analysts also recently issued research reports about the company. Barclays reissued an equal weight rating on shares of Hikma Pharmaceuticals in a report on Monday, November 18th. Peel Hunt restated a hold rating on shares of Hikma Pharmaceuticals in a report on Wednesday, November 27th. Citigroup restated a buy rating on shares of Hikma Pharmaceuticals in a report on Thursday, November 7th. Jefferies Financial Group reaffirmed a buy rating on shares of Hikma Pharmaceuticals in a research report on Friday, November 15th. Finally, Morgan Stanley reiterated an equal weight rating on shares of Hikma Pharmaceuticals in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of GBX 1,798.33 ($23.50).
LON:HIK opened at GBX 1,896 ($24.77) on Tuesday. The firm has a 50-day moving average of GBX 1,944.80 and a two-hundred day moving average of GBX 1,884.40. The company has a debt-to-equity ratio of 37.69, a current ratio of 1.28 and a quick ratio of 0.78. The stock has a market cap of $4.58 billion and a P/E ratio of 12.74. Hikma Pharmaceuticals has a 1-year low of GBX 1,491.50 ($19.49) and a 1-year high of GBX 2,212 ($28.90).
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals.
Featured Story: What does relative strength index mean?
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.